Rocket Pharmaceuticals (RCKT) EPS (Weighted Average and Diluted) (2019 - 2025)
Rocket Pharmaceuticals (RCKT) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.38 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) rose 38.71% to -$0.38 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.01 through Dec 2025, up 26.37% year-over-year, with the annual reading at -$2.01 for FY2025, 26.37% up from the prior year.
- EPS (Weighted Average and Diluted) hit -$0.38 in Q4 2025 for Rocket Pharmaceuticals, up from -$0.45 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.38 in Q4 2025 to a low of -$0.89 in Q4 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.68 across 5 years, with a median of -$0.68 in 2021.
- Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 50.91% in 2022 and later surged 38.71% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.68 in 2021, then crashed by 30.88% to -$0.89 in 2022, then surged by 30.34% to -$0.62 in 2023, then changed by 0.0% to -$0.62 in 2024, then soared by 38.71% to -$0.38 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for RCKT at -$0.38 in Q4 2025, -$0.45 in Q3 2025, and -$0.62 in Q2 2025.